COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This study was designed to determine whether COREG MR is more effective than TOPROL-XL in reducing microalbuminuria in type 2 diabetic or non-diabetic patients with high blood pressure and microalbuminuria.
A Randomized, Double-blind, Positive-Controlled, Multicenter Study Comparing the Efficacy of Carvedilol Phosphate Modified Release Formulation (COREG MR) and Metoprolol Succinate Extended Release (TOPROL-XL) on the Reduction of Microalbuminuria in Patients With Hypertension and Microalbuminuria
Study Start Date
Primary Completion Date
Study Completion Date
Resource links provided by the National Library of Medicine
Change from baseline in urine albumin: creatinine ratio (ACR) at six months of maintenance therapy. [ Time Frame: Baseline (Randomization Visit) and Month 6 ]
Secondary Outcome Measures
Percentage of participants who achieved normoalbuminuria at 6 months of maintenance therapy. [ Time Frame: Month 6 ]
Percentage of participants who progressed to macroalbuminuria after 6 months of maintenance therapy. [ Time Frame: Month 6 ]
Change from baseline to month 6 LOCF in High-sensitivity C-reactive protein (hs-CRP) [ Time Frame: Baseline (Randomization Visit) and Month 6 ]
Change from Pre-screening visit to month 6 LOCF in urine ACR. [ Time Frame: Pre-screening Visit and Month 6 ]
Change from baseline to visit to month 6 LOCF in lipids including total cholesterol, low density lipid (LDL), high density lipid (HDL) and Triglycerides (TG) [ Time Frame: Baseline (Randomization visit) and Month 6 ]
Changes from baseline in blood pressure (systolic and diastolic) at month 6 of treatment. [ Time Frame: Baseline (Randomization Visit) and Month 6 ]
Changes from baseline in heart rate at month 6 of treatment. [ Time Frame: Baseline (Randomization visit) and Month 6 ]
Percentage of participants who required add-on therapy to reach target blood pressure at any time during the study. [ Time Frame: Up to 6 months ]
Number of participants with clinical chemistry parameters and hematology parameters of potential clinical concern at any time on-treatment. [ Time Frame: Up to 6 months ]
Number of participants with vital signs of potential clinical concern at any time on-treatment. [ Time Frame: Up to 6 months ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 80 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Documented history of hypertension.
Must have been taking an ACE (angiotensin converting enzyme) inhibitor either alone or as part of an antihypertensive regimen for at least 8 weeks.
History of heart attack, stroke, congestive heart failure, arrhythmia, type 1 or uncontrolled type 2 diabetes mellitus, liver or renal disease.
Has been taking any non-ocular beta-blockers for any indication within three months prior to Pre-screening.